CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ: CERS) announced today that it has signed a
two-year agreement with the General Hospital of Vienna (AKH) to supply
the INTERCEPT Blood System for platelets. Cerus understands that the AKH
plans to use INTERCEPT to treat the approximately 6000 platelet units it
produces each year, and has already implemented the INTERCEPT process
into their routine production.
“We are honored that the AKH has chosen INTERCEPT as their pathogen
inactivation technology for platelets,” said Caspar Hogeboom, president
of Cerus Europe. “The AKH has a long tradition of providing the highest
standards of care for its patients, and we believe their practices have
influence throughout Austria and the surrounding European region.”
ABOUT GENERAL HOSPITAL OF VIENNA
From: http://www.meduniwien.ac.at/homepage/service/vienna-general-hospital-akh/en/
The
General Hospital of Vienna (AKH) looks back on more than 300 years of
history. The original "Home for the Poor and Invalid" has developed into
one of the most modern and advanced hospitals in Europe. With more than
30 university clinics and clinical institutes, the AKH guarantees
extremely high standards and innovative technologies in all medical
fields. At the AKH, patient care, instruction and research have been
laid down as inseparable and equal elements. The people are always at
the centre of the AKH’s tasks and objectives. See http://www.akhwien.at
for more information.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action enables
INTERCEPT treatment to inactivate established transfusion threats, such
as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed
to inactivate emerging pathogens such as influenza, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions around the
world. The INTERCEPT red blood cell system is in clinical development.
See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
This press release contains forward-looking statements. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to the number of
platelets treated by the AKH using the INTERCEPT Blood System, potential
growth in the use of the INTERCEPT Blood System the potential influence
of the AKH over blood safety technology decisions in Austria and Europe.
These forward-looking statements are based upon Cerus’ current
expectations. Actual results could differ materially from these
forward-looking statements as a result of certain factors, including,
without limitation, risks associated with demand for the INTERCEPT Blood
System, including the risk that Cerus may not be able to maintain its
supply agreement with the AKH, risks associated with Cerus’ ability to
achieve broader market acceptance of its INTERCEPT Blood System
products, adverse decisions or actions by regulatory agencies including
those of Austria, and other risks detailed in the Cerus' filings with,
the Securities and Exchange Commission (SEC), including in Cerus' annual
report on Form 10-K for the year ended December 31, 2011, filed with the
SEC on March 5, 2012. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of
this press release. Cerus does not undertake any obligation to update
any forward-looking statements as a result of new information, future
events, changed assumptions or otherwise.
Source: Cerus Corporation